AP
GPCR icon

Antipodes Partners’s Structure Therapeutics GPCR Stock Holding History

Antipodes Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
51,262
+5,901
+13% +$261K 0.05% 69
2026
Q1 		$2.19M Sell
45,361
-882
-2% -$60.4K 0.04% 66
2025
Q4 		$3.22M Buy
46,243
+42,165
+1,034% +$1.72M 0.07% 65
2025
Q3 		$114K Buy
4,078
+1,146
+39% +$22.8K ﹤0.01% 83
2025
Q2 		$60.8K Sell
2,932
-1,315
-31% -$28.9K ﹤0.01% 82
2025
Q1 		$73.5K Buy
4,247
+3,213
+311% +$78.7K ﹤0.01% 78
2024
Q4 		$28K Buy
1,034
+553
+115% +$19.6K ﹤0.01% 73
2024
Q3 		$21.1K Sell
481
-46
-9% -$1.78K ﹤0.01% 80
2024
Q2 		$20.7K Buy
+527
New +$21.6K ﹤0.01% 75

Other funds holding GPCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Antipodes Partners's GPCR Position: Q2 2026 in Review

Antipodes Partners increased its Structure Therapeutics (GPCR) stake by 13% in Q2 2026, buying an estimated $261K and bringing the position to 51,262 shares worth $2.75M. The position accounts for 0.05% of the portfolio, ranked #69.

Antipodes Partners first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.22M in Q4 2025. 61 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Antipodes Partners held 51,262 shares of Structure Therapeutics worth $2.75M as of Q2 2026.
  • Antipodes Partners bought 5,901 Structure Therapeutics shares in Q2 2026, an estimated $261K.
  • Structure Therapeutics made up 0.05% of Antipodes Partners's portfolio in Q2 2026, its #69 holding.
  • Antipodes Partners first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Antipodes Partners's Structure Therapeutics position peaked at $3.22M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.